FDA-APPROVED PRODUCT THERAPY AREAS

FDA-approved Product

Therapy Areas

At Sanofi, we are redefining immunology from science to treatment. Building on 100 years of expertise in diabetes, we are continuing to push scientific boundaries to improve our understanding of the immune system and bring forward breakthrough medicines that can help improve outcomes for those living with autoimmune T1D.

Educational Resources

Type 1 Diabetes

American Diabetes Association Standards of Care in T1D – 2026
Select updates from section 2 and 3 pertaining to T1D. For a comprehensive overview of all changes, refer to the 2026 Standards of Care

Consensus Guidelines for Monitoring Persons with Islet Autoantibody-Positive Pre-Stage 3 T1D
Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes | Diabetes Care | American Diabetes Association

Adult Onset T1D
Common clinical considerations and/or procedural steps for the diagnosis and management of early-stage T1D adult patients

Infographic: Screening & Staging
Review of the progression of T1D over time, identification of at-risk populations, approaches to autoantibody screening, and available screening test options

Infographic: T1D Monitoring Guidance
Review of target populations for monitoring, key stakeholders involved in monitoring, monitoring across the full continuum of care, and specific considerations for both pediatric and adult populations

Infographic: Beta Cell/C-peptide
Autoimmune type 1 diabetes: The role of beta-cell function and C-peptide assessment

The Value of Beta-Cell Preservation
Overview of C-peptide testing in assessing beta cell function and the implications of beta cell preservation in managing T1D

Infographic: Monitoring Guidance for Pre-Stage 3 T1D
International consensus guidance initiated by Breakthrough T1D: Monitoring and educational goals for islet autoantibody-positive early-stage T1D

Infographic: Operationalize Screening
Best practices for establishing screening programs for presymptomatic T1D

Pipeline and Beta Cell Story
Review of our commitment to autoimmune T1D research: Exploring investigational agents across the stages of T1D disease and assessing their impact on key markers of disease progression

RWE Teplizumab Metabolic and Immunological Outcomes (Stage 2)
Real-world study examining whether glycemic response observed in controlled trials was reproduced in real-world practice and exploring immunological biomarkers associated with treatment

Risk of New-Onset T1D in Individuals with Celiac Disease & Thyroid Disease Study
Study comparing the risk of developing T1D and time to development of T1D in individuals with celiac disease, hyperthyroidism, and hypothyroidism to that of individuals without these conditions of interest